RE: What's Going On?11 Feb 2026 11:26
OBD’s current market cap sits around £12–13m according to recent trading data .
For a company with:
• a validated EpiSwitch platform,
• multiple clinical collaborations,
• and a commercialised test (EpiSwitch CiRT),
And although the valuation is deeply distressed, and not at all reflective of the underlying IP there is a real chance that this will re rate very quickly.
If OBD secures even a modest commercial contract or licensing deal, the rerate could be violent because the base valuation is so low.
The cost‑cutting and restructuring that have been undertaken reduces burn, which will eventually attract value investment to OBD.
OBD has now acknowledged its historically high burn rate and has taken steps to reduce it, including senior staff taking 25% of pay in shares and a review of further cost reductions and asset sales .
A leaner OBD with lower cash burn extends runway and increases the probability of reaching a value‑creating milestone without a dilutive raise.
Further to this a strategic review could unlock hidden value - the company is actively exploring:
• asset sales,
• spin‑offs,
• US business separation,
• alternative funding routes.
All of this was explicitly stated in the funding warning update .
A US spin‑off or asset sale could crystallise value far above the current UK market cap, especially given the UK’s chronic underpricing of life sciences.
Also the UK government has explicitly prioritised bioscience investment as part of its economic strategy, with life sciences highlighted as a key growth sector, a lot of ppl would get very excited if we start any meaningful involvement with the NHS - there are remember trials using OBD products in private healthcare which NHS bodies talk / have involvement with.
OBD is well‑positioned to benefit from:
• grants,
• partnerships,
• government‑backed investment initiatives,
• and improved sector sentiment.
This macro tailwind could lift all UK life‑science microcaps, with OBD being one of the most leveraged to sentiment shifts.
EpiSwitch platform still has commercial potential despite the funding issues, the underlying technology remains:
• validated,
• differentiated,
• and applicable across oncology, immunology, and precision medicine.
If OBD secures even one meaningful commercial partnership (e.g., pharma companion diagnostic), the revenue potential could dwarf the current valuation.
What's not to get slightly excited by the above ??
OSD - Feeling very 'bullish' and why not !!